Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab in PS 2-3 NSCLC
NCT04108026Phase 2Completed
- Sponsor
- IFCT
- Start
- Oct 2020
- Primary completion
- Nov 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by IFCT. Primary endpoint: Proportion of patients experiencing Grade 3-5 Treatment Related Adverse Event at 8 weeks. Started Oct 2020; status: completed.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04108026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04108026.